Related Experiment Videos
Role of COX-2 specific inhibitors in oncogenesis
Abbas Ali Gumgumji1, Talal Dawood, Tariq Parvez
1Department of Gastroenterology, King Fahad Hospital, Al Madina Al Munawra, KSA.
Abstract:
Cyclooxygenase-2 (COX-2) is over expressed in a variety of premalignant and malignant conditions. It may contribute to carcinogenesis by modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. Selective COX-2 inhibitors suppress the formation of tumors in experimental models. Selective COX-2 inhibitors also suppress the growth and metastases of established tumors and enhance the anticancer activity of both radiotherapy and chemotherapy in experimental animals. This review aims at discussing evidence that inhibition of COX-2 represents a promising strategy to treat, prevent or possibly prevent human malignancies. Importantly, selective COX-2 inhibitors do not inhibit platelet function and cause fewer gastrointestinal side effects (peptic ulcer disease) than traditional nonsteroidal anti-inflammatory drugs (NSAIDS). More clinical trials are warranted to define the role of selective COX-2 inhibitors in the prevention and treatment of cancer along with their assessment of toxicity.
Insights
Selective cyclooxygenase-2 (COX-2) inhibitors show promise in cancer prevention and treatment by suppressing tumor formation and growth. These agents offer a safer alternative to traditional NSAIDs with fewer side effects.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cyclooxygenase-2 (COX-2) is overexpressed in various premalignant and malignant conditions.
- COX-2 may promote carcinogenesis through its influence on xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis.
Purpose of the Study:
- To review the evidence supporting COX-2 inhibition as a strategy for preventing and treating human malignancies.
- To discuss the potential of selective COX-2 inhibitors in cancer therapy.
Main Methods:
- Review of experimental models and preclinical data on selective COX-2 inhibitors.
- Analysis of the role of COX-2 in carcinogenesis and tumor progression.
Main Results:
- Selective COX-2 inhibitors suppress tumor formation in experimental models.
- These inhibitors also reduce the growth and metastasis of established tumors.
- They enhance the efficacy of radiotherapy and chemotherapy in preclinical studies.
Conclusions:
- Inhibition of COX-2 presents a promising strategy for the prevention and treatment of human cancers.
- Selective COX-2 inhibitors exhibit a favorable safety profile compared to traditional NSAIDs, with reduced gastrointestinal side effects and no impact on platelet function.
- Further clinical trials are necessary to establish the definitive role and optimal use of selective COX-2 inhibitors in cancer care.